{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"726","value":"106"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"description":"Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status \\& survival. Pts who did not have response assessments after baseline were censored at treatment day 1.","dispersionType":"Full Range","groups":[{"description":"All patients who received at least one dose of pralatrexate and had an eligible PTCL histopathological subtype confirmed by central pathology review.","id":"OG000","title":"Evaluable Population"}],"paramType":"MEDIAN","populationDescription":"Analysis was per protocol, based on the number of patients (pts) who had an event of progressive disease (PD) or death. Pts who did not have an event at the time of data cut-off were censored. Pts were censored for lack of PD, receipt of other anti-cancer therapy before PD, termination of study/follow-up for response, and transplant.","reportingStatus":"POSTED","timeFrame":"Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose","title":"Progression-free Survival Per Independent Central Review","type":"SECONDARY","unitOfMeasure":"Days"}